Thathiah et al. describes the GPCR receptors as direct modulators of α-, β- and γ-secretases, APP (amyloid precursor protein) processing, and amyloid-β degradation, and have suggests that GPCRs could serve as a prospective therapeutic target for treating AD [11,55]. Here, APP is linked to Alzheimer disease.